Enter multiple symbols separated by commas

Schering-Plough, Merck Say Allergy-Drug Filing Accepted

Schering-Plough and Merck Tuesday said U.S. regulators had accepted the marketing application for their experimental allergy drug, which combines two widely used existing treatments into a single tablet.

A joint venture between the two drugmakers is developing the product, which includes the active ingredients of Schering-Plough's Claritin allergy medicine and Merck's Singulair treatment for allergy and asthma.

The partners said the combination product would receive a standard review by the U.S. Food and Drug Administration -- which typically means the agency will respond within 10 months.

The active ingredient of Claritin, loratadine, is an antihistamine sold by a number of companies in over-the-counter forms.

The active ingredient of Singulair, a $4 billion-a-year drug available by prescription, is called montelukast. It works by controlling proteins called leukotrienes, which also trigger allergic symptoms such as stuffy nose and sneezing.

The Schering-Plough/Merck joint venture successfully developed and now sells Zetia and Vytorin, two popular cholesterol fighters that have been linchpins of growing profitability for the two drugmakers.

Contact Health Care


    Get the best of CNBC in your inbox

    Please choose a subscription

    Please enter a valid email address
    To learn more about how we use your information,
    please read our Privacy Policy.